Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125424971 | 12542497 | 1 | I | 20131015 | 20160709 | 20160709 | EXP | US-CIPLA LTD.-2014US00246 | CIPLA | TARHINI AA, ZAHOOR H, MCLAUGHLIN B, GOODING WE, SCHMITZ JC, SIEGFRIED JM, ET AL;. PHASE I TRIAL OF CARBOPLATIN AND ETOPOSIDE IN COMBINATION WITH PANOBINOSTAT IN PATIENTS WITH LUNG CANCER. ANTICANCER RESEARCH. 2013;33:4475 TO 4482 | 0.00 | Y | 0.00000 | 20160709 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125424971 | 12542497 | 1 | PS | CARBOPLATIN. | CARBOPLATIN | 1 | Unknown | AUC 5 ON DAY 1, EVERY 21 DAYS | U | 77383 | |||||||||
| 125424971 | 12542497 | 2 | SS | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | Unknown | UNK, PRIOR THERAPY | 0 | ||||||||||
| 125424971 | 12542497 | 3 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | Unknown | 100 MG/M2, ON DAYS 1, 2 AND 3 EVERY 21 DAYS | U | 0 | 100 | MG/M**2 | |||||||
| 125424971 | 12542497 | 4 | SS | CISPLATIN. | CISPLATIN | 1 | Unknown | UNK, PRIOR THERAPY | 0 | ||||||||||
| 125424971 | 12542497 | 5 | SS | DOCETAXEL. | DOCETAXEL | 1 | Unknown | UNK, PRIOR THERAPY | 0 | ||||||||||
| 125424971 | 12542497 | 6 | SS | PACLITAXEL. | PACLITAXEL | 1 | Unknown | UNK, PRIOR THERAPY | 0 | ||||||||||
| 125424971 | 12542497 | 7 | SS | Panobinostat | PANOBINOSTAT | 1 | Oral | 10 MG, 3 TIMES WEEKLY, 2 WEEKS ON 1 WEEK OFF | U | 0 | 10 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125424971 | 12542497 | 1 | Non-small cell lung cancer stage IV |
| 125424971 | 12542497 | 2 | Non-small cell lung cancer stage IV |
| 125424971 | 12542497 | 3 | Non-small cell lung cancer stage IV |
| 125424971 | 12542497 | 4 | Non-small cell lung cancer stage IV |
| 125424971 | 12542497 | 5 | Non-small cell lung cancer stage IV |
| 125424971 | 12542497 | 6 | Non-small cell lung cancer stage IV |
| 125424971 | 12542497 | 7 | Non-small cell lung cancer stage IV |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125424971 | 12542497 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125424971 | 12542497 | Disease progression | |
| 125424971 | 12542497 | Febrile neutropenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |